Clinimetric Properties of Outcome Measures in Bronchiectasis-Reference-Cited by-同舟云学术

Clinimetric Properties of Outcome Measures in Bronchiectasis

Published:2023-05 Issue:5 Volume:20 Page:648-659
ISSN:2329-6933
Container-title:Annals of the American Thoracic Society
language:en
Short-container-title:Annals ATS

Author:

Bradley Judy M.¹²^ORCID,Ferguson Kathryn³,Bailey Andrew⁴,O’Neill Katherine¹,McLeese Rebecca H.²,Hill Adam T.⁵⁶,Loebinger Michael R.⁷,Carroll Mary⁸,Chalmers James D.⁹,Gatheral Timothy¹⁰,Johnson Christopher¹¹,De Soyza Anthony¹²,Hurst John R.¹³,Downey Damian G.¹,Elborn J. Stuart¹⁷

Affiliation:

1. Wellcome-Wolfson Institute for Experimental Medicine and

2. Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility, Queen’s University Belfast, Belfast, United Kingdom;

3. Northern Ireland Clinical Research Network, Belfast Health and Social Care Trust, Belfast, United Kingdom;

4. Frontier Science Ltd., Kincraig, United Kingdom;

5. Royal Infirmary of Edinburgh, Edinburgh, United Kingdom;

6. Department of Respiratory Medicine, Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom;

7. Host Defence Unit, Royal Brompton Hospital, Imperial College London, London, United Kingdom;

8. University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom;

9. College of Medicine, University of Dundee, Dundee, United Kingdom;

10. Department of Respiratory Medicine, University Hospitals of Morecambe Bay NHS Foundation Trust, Kendal, United Kingdom;

11. Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, United Kingdom;

12. Population and Health Science Institute, National Institute of Health Research Biomedical Research Centre on Ageing, Newcastle University, Newcastle, United Kingdom; and

13. Department of Respiratory Medicine, University College London, London, United Kingdom

Funder

Medical Research Council

Innovative Medicines Initiative

Publisher

American Thoracic Society

Subject

Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1513/AnnalsATS.202206-493OC

Reference39 articles.

1. Short- and Long-Term Antibiotic Treatment Reduces Airway and Systemic Inflammation in Non–Cystic Fibrosis Bronchiectasis

2. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial

3. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials

4. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials

5. The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Airway Total Bacterial Density, Microbiota Community Composition and Relationship with Clinical Parameters in Bronchiectasis;2024